A Canadian Retrospective Chart Review Evaluating Concomitant Methotrexate De-escalation Patterns in Patients with Rheumatoid Arthritis Treated with Biologic or Targeted Synthetic DMARDs

Abstract Introduction Rheumatoid arthritis (RA) guidelines recommend methotrexate (MTX)-anchored therapy with biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs); however, tolerability issues often lead to non-adherence. Canadian data on MTX tapering and/or withdrawal f...

Full description

Bibliographic Details
Published in:	Rheumatology and Therapy
Main Authors:	Louis Bessette, Brandusa Florica, Latha Naik, Dalton Sholter, Pierre-André Fournier, Tanya Girard, Dalinda Liazoghli, Philip A. Baer
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2024-07-01
Subjects:	Rheumatoid arthritis Methotrexate Therapy Antirheumatic agents
Online Access:	https://doi.org/10.1007/s40744-024-00696-9

Similar Items

Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero’s adalimumab (Mabura®, Hetero Biopharma Ltd.) and reference adalimumab (Humira®, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy
by: Shubhadeep Sinha, et al.
Published: (2020-06-01)

Short time administration of antirheumatic drugs - Methotrexate as a strong inhibitor of osteoblast's proliferation in vitro
by: Annussek Tobias, et al.
Published: (2012-09-01)

Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials
by: John Tesser, et al.
Published: (2023-11-01)

Early rheumatoid arthritis therapy: comparative characteristic of delagil, sulphasalazine and methotrexate
by: T S Salnikova, et al.
Published: (2003-08-01)

Comparison of the efficacy and safety of methotrexate alone or in combination with leflunomide in the treatment of juvenile idiopathic arthritis: a double-blind, placebo-controlled, randomized trial
by: Zahra Rezaieyazdi, et al.
Published: (2023-03-01)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
by: Juthamas Prawjaeng, et al.
Published: (2023-05-01)

Antirheumatic Medication Calendar Significantly Improves Adherence in First-Time Methotrexate Users: A Prospective, Single-Blind, Randomized Controlled Trial
by: Yuan F, et al.
Published: (2025-07-01)

Predictor Response of Monotherapy with Methotrexate with Triple DMARDS Therapy in Patients of Rheumatoid Arthritis
by: Babar Ejaz, et al.
Published: (2025-01-01)

Analysis of methotrexate use practice in patients with rheumatoid and psoriatic arthritis
by: S. A. Doktorova, et al.
Published: (2025-05-01)

Efficacy and safety of rapid dose escalation of methotrexate in rheumatoid arthritis. Results of the multicenter “METEOR” study
by: V. N. Amirjanova, et al.
Published: (2025-03-01)

Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting
by: Rieke Alten, et al.
Published: (2018-01-01)

Achievement of minimal disease activity in psoriatic arthritis according to the time of administration of synthetic disease-modifying antirheumatic drugs, a comparative analysis of the efficacy of oral and subcutaneous methotrexate. Data from the All-Russian Psoriatic Arthritis Registry
by: T. V. Korotaeva, et al.
Published: (2021-02-01)

Efficacy of withdrawal or tapering of bDMARDs vs. standard regimen in axial spondyloarthritis patients: systematic review and meta-analysis informing the update of the Spanish Society of Rheumatology Guideline
by: Hye Sang Park, et al.
Published: (2025-09-01)

NEW GUIDELINES FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS (EULAR, 2013): THE PLACE OF GLUCOCORTICOIDS
by: E. L. Nasonov
Published: (2015-09-01)

NEW GUIDELINES FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS (EULAR, 2013): THE PLACE OF GLUCOCORTICOIDS
by: E. L. Nasonov
Published: (2015-10-01)

NEW GUIDELINES FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS (EULAR, 2013): THE PLACE OF GLUCOCORTICOIDS
by: E. L. Nasonov
Published: (2016-12-01)

Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis
by: Yinan Huang, et al.
Published: (2023-09-01)

Biomarkers to Personalize the Treatment of Rheumatoid Arthritis: Focus on Autoantibodies and Pharmacogenetics
by: Valeria Conti, et al.
Published: (2020-12-01)

Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry
by: Denis Choquette, et al.
Published: (2019-06-01)

Comparison of the Efficacy and Safety of Disease‐Modifying Antirheumatic Drugs Combination Therapies: A Systematic Review and Network Meta‐Analysis
by: Linfeng Liu, et al.
Published: (2025-03-01)

Rheumatoid arthritis: problems of treatment at the present stage
by: N. V. Chichasova
Published: (2018-12-01)

Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An extension study
by: Małgorzata Wisłowska
Published: (2024-11-01)

High-dose methotrexate
by: Manikandan Dhanushkodi
Published: (2019-01-01)

Methotrexate
by: Nilgün Şentürk
Published: (2022-04-01)

Difficult-to-treat rheumatoid arthritis: Current concept and unsolved problems
by: Ryu Watanabe, et al.
Published: (2022-10-01)

Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis
by: Paul Emery, et al.
Published: (2023-03-01)

Genetic polymorphisms as predictors of methotrexate toxicity: literature review
by: G. A. Radzhabova, et al.
Published: (2024-04-01)

Optimizing Secukinumab Treatment in Psoriasis with Concomitant Methotrexate Administration: Minireview and A Case Report
by: Dimitra Kostaki, et al.
Published: (2019-09-01)

Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents
by: Marco Infante, et al.
Published: (2022-04-01)

Dose Adjustment of Methotrexate Administered Concomitantly with Golimumab for Rheumatoid Arthritis in Japanese Real-World Clinical Settings
by: Fumiko Yamairi, et al.
Published: (2020-08-01)

Disease Activity in Disease Modifying Anti-Rheumatic Drug (DMARD) Naïve Rheumatoid Arthritis Patients in A Subset of Karachi Population
by: Dr. Mehreen Inam Illahi, et al.
Published: (2024-05-01)

Managing Disease-Modifying Antirheumatic Drugs (DMARDs) for Patients Undergoing Elective Spine Surgery: A Pilot Survey
by: James C. Mamaril-Davis, et al.
Published: (2024-01-01)

Risks of Oral Methotrexate Administration in Outpatients
by: Maria Ganeva, et al.
Published: (2014-11-01)

Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
by: Tiina Levälampi, et al.
Published: (2023-03-01)

The Effect of Disease-modifying Antirheumatic Drugs (DMARDs) on the Expression and Methylation Status of the FOXO1 gene in Newly Diagnosed Patients with Rheumatoid Arthritis
by: Shirin Assar1comma, et al.
Published: (2024-09-01)

Latent Tuberculosis Infection in Inflammatory Rheumatic Diseases Before Biological and Synthetic DMARD Treatment: Results from Three Rheumatology Centers in Different Regions of Türkiye
by: Abdulvahap Kahveci, et al.
Published: (2025-07-01)

Prevalence of methotrexate intolerance among patients with rheumatoid arthritis in Erbil city using methotrexate intolerance severity score
by: Zhala Kakamin Mawlood, et al.
Published: (2024-03-01)

Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?
by: Chen HH, et al.
Published: (2016-02-01)

Intra-amniotic and systemic administration of methotrexate with concomitant surgical evacuation of 11 + 5 weeks cervical ectopic pregnancy: a case report
by: Ahmed Sameh Moustafa Ghoubara, et al.
Published: (2023-07-01)

DMOADs and DMARDs in the treatment of patients with joint and spine diseases
by: O. A. Shavlovskaya
Published: (2024-02-01)